title: Update on Mineral and Bone Disorders in Chronic Kidney Disease.
abstract: The inappropriate phosphorus retention observed in chronic kidney disease is central to the pathophysiology of mineral and bone disorders observed in these patients. Subsequent derangements in serum fibroblast growth factor 23, parathyroid hormone, and calcitriol concentrations play contributory roles. Therapeutic intervention involves dietary phosphorus restriction and intestinal phosphate binders in order to correct phosphorus retention and maintain normocalcemia. Additional therapies may be considered to normalize serum fibroblast growth factor 23 and parathyroid hormone.
authors.affiliation: Department of Clinical Studies, University of Pennsylvania School of Veterinary Medicine, 3900 Delancey Street, Philadelphia, PA 19104, USA. Electronic address: fosterjo@vet.upenn.edu.
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Foster
mesh_terms: D000818:Animals; D002371:Cat Diseases / Q000209:etiology*; D002415:Cats; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000473:pathology / Q000662:veterinary*; D004283:Dog Diseases / Q000209:etiology*; D004285:Dogs; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000662:veterinary*
keywords: Fibroblast growth factor 23; Hyperphosphatemia; Renal osteodystrophy; Renal secondary hyperparathyroidism